The fusion of CALM (clathrin-assembly protein-like lymphoidmyeloid) and AF10 genes was first shown in the leukemia cell line U937 to be the result of chromosomal translocation t(10;11)(p13;q14-21).
1 CALM-AF10 fusion transcripts have been reported in both acute lymphoblastic and myeloid leukemia (ALL and AML). 2 The presence of CALM-AF10 fusion in a 6-year-old boy with acute megakaryoblastic leukemia (AMKL) without Down's syndrome has been reported previously. 3 Between January 2000 and September 2006, seven cases of AMKL out of 398 cases of leukemia, including 75 cases of AML, presented to the Hospital for Sick Children in Toronto. Five of the seven AMKL cases occurred in children with Down's syndrome and has no evidence of t(10;11)(p13;q14-21). In the other two cases of AMKL in children without Down's syndrome, the leukemia blasts harbored t(10;11)(p13;q14-21) in addition to other cytogenetic abnormalities. Case 1 was a 4-year-old girl and case 2 was a 2-year-old boy. The bone marrow aspirates from both cases were infiltrated by blasts with characteristic morphological features of megakaryoblasts. The immunophenotype of the blast populations from both cases were identical and consistent with AMKL: positive for CD41a, CD61, CD33, HLA-DR, CD4 and CD7 and negative for other myeloid, T and B lineage markers. In addition, the blasts from case 2 also expressed CD34.
We used a previously described reverse transcription-polymerase chain reaction (RT-PCR) protocol 4 followed by nucleotide sequence analysis to show the involvement of CALM and AF10 genes in both non-Down's syndrome AMKL cases. Case 1 had the same fusion transcripts seen in the control cell line U937 (Figure 1 ). Case 2 shows the presence of a major product resulting from a novel inframe fusion of CALM (position 2091 of Genbank entry U45976.1) to AF10 (position 796 of Genbank entry AY598745). Except for CD34 expression, differences in breakpoints do not seem to affect the immunophenotype. Both patients achieved remission following induction chemotherapy.
It has been suggested that CALM-AF10 fusion is common in T-cell ALL and is specific for T-cell receptor (TCR)gd T lineage. RT-PCR testing for CAM-AF10 fusion transcripts. The reactions were performed according to the protocol described by Asnafi et al. 4 No products were noted in the negative control. Case 1 shows the presence of three products similar to those seen in the control cell line U937. Case 2 shows the presence of a major product resulting from a novel inframe fusion of CALM and AF10 (Genbank accession no. EF051633). Indoleamine 2,3-dioxygenase (IDO) is a key enzyme in the tryptophan metabolism, which catalyzes the initial rate-limiting step of tryptophan degradation along the kynurenine pathway.
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Tryptophan starvation by IDO consumption inhibits T-cell activation, 1,2 whereas products of tryptophan catabolism, such as kynurenine derivatives and O 2 free radicals, regulate T-cell proliferation and survival. Letters to the Editor
